Gene Therapy Market by Type (Gene silencing, Gene augmentation), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Therapeutic Area (Neurology, Oncology), Delivery Method (In-vivo, Ex-vivo), RoA (Intravenous) & Region - Global Forecast to 2028
The gene therapy market is expected to reach USD 23.9 billion by 2028 from USD 9.0 billion in 2023, at a CAGR of 21.4% during the forecast period. The key factors driving the growth of the gene therapy market include increasing initiatives related to genomic research, and increasing number of regulatory approvals for gene therapy products. Moreover, growing demand for cell and gene therapies is an opportunity area for this market.
The gene therapy market has been segmented based on type, vector, therapeutic area, delivery method, route of administration and region.
“By therapeutic area, oncology segment accounted for the second largest share of the gene therapy market”
Based on type, the gene therapy market is categorized into neurology, oncology, hepatology, and other therapeutic areas.. In 2022, oncology accounted for the highest growth rate owing to factors such as The rising demand for targeted therapies (including gene therapy) against cancer, increasing cancer prevalence are the major factors driving the growth of this segment.
“By delivery method, the in vivo segment accounted for the largest share in the gene therapy market”
Based on end user, the gene therapy market is segmented into the gene therapy market is segmented into in vivo and ex vivo. In 2022, the in vivo segment accounted for a largest share of the gene therapy market. Growth in this market segment can be attributed to availability of many in vivo gene therapy products commercially and focus of research and development on this delivery method.
“North America: the largest share of the gene therapy market”
North America accounted for the largest share of the gene therapy market. The large share of the North America region can be attributed to major factors such presence of technologically advanced infrastructure in healthcare settings offering gene therapies, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market. Also, presence of some of the key players in the market is another key factor. Some examples of these players include Novartis AG (Switzerland), Biogen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US) among others.
“Europe: The fastest-growing region in the gene therapy market.”
The Europe gene therapy market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for advancements of gene therapies, increasing prevalence of chronic diseases and support offered by the government organizations for developing advanced targeted therapies.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the gene therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, indication, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the gene therapy market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers”
The gene therapy market has been segmented based on type, vector, therapeutic area, delivery method, route of administration and region.
“By therapeutic area, oncology segment accounted for the second largest share of the gene therapy market”
Based on type, the gene therapy market is categorized into neurology, oncology, hepatology, and other therapeutic areas.. In 2022, oncology accounted for the highest growth rate owing to factors such as The rising demand for targeted therapies (including gene therapy) against cancer, increasing cancer prevalence are the major factors driving the growth of this segment.
“By delivery method, the in vivo segment accounted for the largest share in the gene therapy market”
Based on end user, the gene therapy market is segmented into the gene therapy market is segmented into in vivo and ex vivo. In 2022, the in vivo segment accounted for a largest share of the gene therapy market. Growth in this market segment can be attributed to availability of many in vivo gene therapy products commercially and focus of research and development on this delivery method.
“North America: the largest share of the gene therapy market”
North America accounted for the largest share of the gene therapy market. The large share of the North America region can be attributed to major factors such presence of technologically advanced infrastructure in healthcare settings offering gene therapies, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market. Also, presence of some of the key players in the market is another key factor. Some examples of these players include Novartis AG (Switzerland), Biogen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US) among others.
“Europe: The fastest-growing region in the gene therapy market.”
The Europe gene therapy market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for advancements of gene therapies, increasing prevalence of chronic diseases and support offered by the government organizations for developing advanced targeted therapies.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, Directors- 30%, and Executives - 25%
- By Country: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 3% & Africa- 2%
- Novartis AG (Switzerland)
- Biogen Inc. (US)
- Gilead Sciences, Inc. (US)
- Bristol-Myers Squibb (US)
- Alnylam Pharmaceuticals, Inc. (US)
- Sarepta Therapeutics, Inc. (US)
- Amgen, Inc. (US)
- Orchard Therapeutics Plc (UK)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Jazz Pharmaceuticals Plc (Ireland)
- uniQure N.V. (Netherlands)
- Johnson & Johnson (US)
- Bluebird Bio, Inc. (US)
- BioMarin Pharmaceutical Inc. (US)
- Krystal Biotech, Inc. (US)
- Shanghai Sunway Biotech Co. Ltd. (China)
- SIBIONO GeneTech Co. Ltd. (China)
- Ferring B.V. (Switzerland)
- Vertex Pharmaceuticals Incorporated (US)
- Pfizer, Inc. (US)
- Sangamo Therapeutics, Inc. (US)
- REGENXBIO (US)
- Ultragenyx Pharmaceutical Inc. (US)
- MeiraGTx Holdings Plc (US)
- AnGes, Inc. (Japan)
This report provides a detailed picture of the gene therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, indication, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the gene therapy market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers”
- Analysis of key drivers (growth in regulatory approvals for gene therapy products), opportunities (cell and gene therapy demand), restraint (budget constraints) and challenges (challenges associated with supply chain) influencing the growth of the gene therapy market.
- Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the gene therapy market.
- Market Development: Comprehensive information about lucrative markets- the report analyses the gene therapy market across varied regions.
- Market Diversification: Exhaustive information about new products and service, untapped geographies, recent developments, and investments in the gene therapy market.
- Analysis of clinical pipeline data and data on products estimated to be launched during the forecast period.
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Novartis AG (Switzerland), Biogen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Amgen, Inc. (US), Orchard Therapeutics Plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), among others in the gene therapy market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 GENE THERAPY MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 GENE THERAPY MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION OF GENE THERAPY MARKET
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
FIGURE 5 MARKET SIZE ESTIMATION FOR GENE THERAPY MARKET: REVENUE SHARE ANALYSIS
2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH FORECAST
FIGURE 8 GENE THERAPY MARKET: CAGR PROJECTIONS
FIGURE 9 GENE THERAPY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
3 EXECUTIVE SUMMARY
FIGURE 11 GENE THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 12 GENE THERAPY MARKET, BY VECTOR, 2023 VS. 2028 (USD MILLION)
FIGURE 13 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
FIGURE 14 GENE THERAPY MARKET, BY DELIVERY METHOD, 2023 VS. 2028 (USD MILLION)
FIGURE 15 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF GENE THERAPY MARKET
4 PREMIUM INSIGHTS
4.1 GENE THERAPY MARKET OVERVIEW
FIGURE 17 INCREASING INVESTMENTS IN GENE THERAPY RESEARCH TO DRIVE GROWTH IN GENE THERAPY MARKET
4.2 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA & COUNTRY (2022)
FIGURE 18 NEUROLOGY ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
4.3 GENE THERAPY MARKET, BY VECTOR, 2022
FIGURE 19 VIRAL VECTORS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 GENE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 GENE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing regulatory approvals for gene therapy products
TABLE 2 LIST OF KEY PRODUCT APPROVALS IN GENE THERAPY MARKET, 2021–2023
5.2.1.2 Increasing investments in gene therapy research
5.2.1.3 Growing technological advancements
TABLE 3 LIST OF ADVANCED PLATFORMS LAUNCHED IN GENE THERAPY MARKET, 2022–2023
5.2.1.4 Rising prevalence of genetic disorders and cancer
5.2.2 RESTRAINTS
5.2.2.1 High cost of gene therapy products
TABLE 4 COST OF GENE THERAPY PRODUCTS
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for cell & gene therapies
5.2.3.2 Increasing focus on precision medicine
5.2.4 CHALLENGES
5.2.4.1 Complex manufacturing process
5.2.4.2 Short shelf life and supply chain challenges
5.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 GENE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 TECHNOLOGY ANALYSIS
5.5 VALUE CHAIN ANALYSIS
FIGURE 22 GENE THERAPY MARKET: VALUE CHAIN
5.6 ECOSYSTEM ANALYSIS
FIGURE 23 GENE THERAPY MARKET: ECOSYSTEM MAP
5.7 PATENT ANALYSIS
FIGURE 24 PATENT APPLICATIONS FOR GENE THERAPY PRODUCTS, JANUARY 2012–SEPTEMBER 2023
TABLE 6 GENE THERAPY MARKET: INDICATIVE LIST OF PATENTS
5.8 PIPELINE ANALYSIS
TABLE 7 GENE THERAPY PRODUCTS IN CLINICAL PIPELINE
5.9 SUPPLY CHAIN ANALYSIS
FIGURE 25 GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS
TABLE 8 SUPPLY CHAIN ECOSYSTEM
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY ANALYSIS
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS
TABLE 13 AVERAGE SELLING PRICE OF GENE THERAPY PRODUCTS
TABLE 14 AVERAGE SELLING PRICE OF GENE THERAPY PRODUCTS, BY DELIVERY METHOD
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13 KEY CONFERENCES & EVENTS
TABLE 15 GENE THERAPY MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023–2024)
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS ON BUYING PROCESS
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR GENE THERAPY PRODUCTS IN HOSPITALS AND CLINICS
5.14.2 BUYING CRITERIA FOR GENE THERAPY MARKET
FIGURE 27 KEY BUYING CRITERIA FOR HOSPITALS AND CLINICS
6 GENE THERAPY MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 16 GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
6.2 GENE SILENCING
6.2.1 HIGH FLEXIBILITY AND PRECISION OFFERED BY GENE SILENCING THERAPIES TO SUPPORT GROWTH
TABLE 17 GENE SILENCING THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 18 NORTH AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 19 EUROPE: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 20 ASIA PACIFIC: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 21 LATIN AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 CELL REPLACEMENT
6.3.1 LONG-TERM EFFECTS OF CELL REPLACEMENT THERAPY TO BOOST ADOPTION
TABLE 22 CELL REPLACEMENT THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 23 NORTH AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 EUROPE: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 ASIA PACIFIC: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 LATIN AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 GENE AUGMENTATION
6.4.1 GROWING USE OF GENE AUGMENTATION THERAPY AGAINST MONOGENIC DISORDERS TO FAVOR MARKET GROWTH
TABLE 27 GENE AUGMENTATION THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 28 NORTH AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 EUROPE: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 ASIA PACIFIC: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 LATIN AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.5 OTHER THERAPIES
7 GENE THERAPY MARKET, BY VECTOR
7.1 INTRODUCTION
TABLE 32 GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
7.2 VIRAL VECTORS
TABLE 33 GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 34 GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 35 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 LATIN AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.1 RETROVIRAL VECTORS
TABLE 39 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 40 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 41 NORTH AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 LATIN AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.1.1 Gamma retroviral vectors
7.2.1.1.1 Availability of wide range of gamma-retroviral vectors to support market growth
TABLE 45 GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 46 NORTH AMERICA: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 EUROPE: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 ASIA PACIFIC: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 49 LATIN AMERICA: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.1.2 Lentiviral vectors
7.2.1.2.1 North America to dominate lentiviral vectors market
TABLE 50 GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 51 NORTH AMERICA: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 LATIN AMERICA: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.2 ADENO-ASSOCIATED VIRAL VECTORS
7.2.2.1 Growing clinical pipeline of adeno-associated viral vectors to drive growth
TABLE 55 GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 56 NORTH AMERICA: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 57 EUROPE: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 ASIA PACIFIC: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 LATIN AMERICA: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.3 OTHER VIRAL VECTORS
TABLE 60 GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 61 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 EUROPE: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 NON-VIRAL VECTORS
TABLE 65 GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 66 GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 67 NORTH AMERICA: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 68 EUROPE: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 69 ASIA PACIFIC: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 LATIN AMERICA: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.3.1 OLIGONUCLEOTIDES
7.3.1.1 Oligonucleotides to account for largest share of non-viral vectors market
TABLE 71 GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY REGION, 2021–2028 (USD MILLION)
TABLE 72 NORTH AMERICA: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 73 EUROPE: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 74 ASIA PACIFIC: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 75 LATIN AMERICA: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021–2028 (USD MILLION)
7.3.2 OTHER NON-VIRAL VECTORS
TABLE 76 GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 77 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 EUROPE: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
8 GENE THERAPY MARKET, BY THERAPEUTIC AREA
8.1 INTRODUCTION
TABLE 81 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.2 NEUROLOGY
8.2.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH
TABLE 82 GENE THERAPY MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 83 NORTH AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 EUROPE: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 86 LATIN AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 ONCOLOGY
8.3.1 GROWING DEMAND FOR TARGETED THERAPIES AGAINST CANCERS TO DRIVE MARKET GROWTH
TABLE 87 PIPELINE PRODUCTS FOR ONCOLOGY APPLICATIONS
TABLE 88 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040
TABLE 89 GENE THERAPY MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 90 NORTH AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 91 EUROPE: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 92 ASIA PACIFIC: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 93 LATIN AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 HEPATOLOGY
8.4.1 GROWING R&D ACTIVITIES FOR LIVER CONDITIONS TO SUPPORT GROWTH
TABLE 94 GENE THERAPY MARKET FOR HEPATOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 95 NORTH AMERICA: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 EUROPE: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 ASIA PACIFIC: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 98 LATIN AMERICA: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
8.5 OTHER THERAPEUTIC AREAS
TABLE 99 GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)
TABLE 100 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 EUROPE: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 102 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
9 GENE THERAPY MARKET, BY DELIVERY METHOD
9.1 INTRODUCTION
TABLE 104 GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
9.2 IN VIVO
9.2.1 IN VIVO DELIVERY METHOD TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
TABLE 105 COMMERCIALIZED AND PIPELINE IN VIVO-BASED GENE THERAPY PRODUCTS
TABLE 106 IN VIVO GENE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 107 NORTH AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 108 EUROPE: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 109 ASIA PACIFIC: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 110 LATIN AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 EX VIVO
9.3.1 GROWING FOCUS ON ONCOLOGY BY MARKET PLAYERS TO SUPPORT MARKET GROWTH
TABLE 111 COMMERCIALIZED AND PIPELINE EX VIVO-BASED GENE THERAPY PRODUCTS
TABLE 112 EX VIVO GENE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 113 NORTH AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 114 EUROPE: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 115 ASIA PACIFIC: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 116 LATIN AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION
10.1 INTRODUCTION
TABLE 117 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
10.2 INTRAVENOUS
10.2.1 EFFECTIVENESS OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH
TABLE 118 GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 119 NORTH AMERICA: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 120 EUROPE: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 121 ASIA PACIFIC: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 122 LATIN AMERICA: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
10.3 OTHER ROUTES OF ADMINISTRATION
TABLE 123 GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 124 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 125 EUROPE: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 126 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 127 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
11 GENE THERAPY MARKET, BY REGION
11.1 INTRODUCTION
TABLE 128 GENE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT
TABLE 129 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 130 NORTH AMERICA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 131 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 132 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 133 NORTH AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 134 NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 135 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 136 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 137 NORTH AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.2.1 US
11.2.1.1 Growing regulatory approvals and availability of advanced treatments to drive market growth
TABLE 138 US FDA APPROVALS FOR GENE THERAPY PRODUCTS
TABLE 139 US: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 140 US: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 141 US: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 142 US: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 143 US: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 144 US: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 145 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 146 US: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Growing gene therapy research initiatives to support growth
TABLE 147 CANADA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 148 CANADA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 149 CANADA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 150 CANADA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 151 CANADA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 152 CANADA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 153 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 154 CANADA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.2.3 NORTH AMERICA: RECESSION IMPACT
11.3 EUROPE
FIGURE 29 EUROPE: GENE THERAPY MARKET SNAPSHOT
TABLE 155 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 156 EUROPE: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 157 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 158 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 159 EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 160 EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 161 EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 162 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 163 EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Growing collaborations in market to boost growth
TABLE 164 GERMANY: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 165 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 166 GERMANY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 167 GERMANY: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 168 GERMANY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 169 GERMANY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 170 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 171 GERMANY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.2 UK
11.3.2.1 Strong government support to drive market growth
TABLE 172 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 173 UK: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 174 UK: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 175 UK: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 176 UK: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 177 UK: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 178 UK: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 179 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 180 UK: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Increasing initiatives in genomic research to drive market
TABLE 181 FRANCE: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 182 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 183 FRANCE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 184 FRANCE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 185 FRANCE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 186 FRANCE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 187 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 188 FRANCE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Initiatives for gene therapy development to drive growth
TABLE 189 ITALY: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 190 ITALY: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 191 ITALY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 192 ITALY: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 193 ITALY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 194 ITALY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 195 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 196 ITALY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Genomics initiatives and funding to support market growth
TABLE 197 SPAIN: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 198 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 199 SPAIN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 200 SPAIN: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 201 SPAIN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 202 SPAIN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 203 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 204 SPAIN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 205 REST OF EUROPE: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 206 REST OF EUROPE: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 207 REST OF EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 208 REST OF EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 209 REST OF EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 210 REST OF EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 211 REST OF EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 212 REST OF EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.7 EUROPE: RECESSION IMPACT
11.4 ASIA PACIFIC
TABLE 213 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 214 ASIA PACIFIC: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 215 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 216 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 217 ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 218 ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 219 ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 220 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 221 ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.4.1 CHINA
11.4.1.1 China to dominate gene therapy market in APAC during forecast period
TABLE 222 CHINA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 223 CHINA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 224 CHINA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 225 CHINA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 226 CHINA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 227 CHINA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 228 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 229 CHINA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Increasing initiatives supporting gene therapy adoption to propel market growth
TABLE 230 JAPAN: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 231 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 232 JAPAN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 233 JAPAN: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 234 JAPAN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 235 JAPAN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 236 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 237 JAPAN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Increasing burden of chronic diseases to drive market growth
TABLE 238 INDIA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 239 INDIA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 240 INDIA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 241 INDIA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 242 INDIA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 243 INDIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 244 INDIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 245 INDIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 246 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 247 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 248 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 249 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 250 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 251 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 252 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 253 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.4.5 ASIA PACIFIC: RECESSION IMPACT
11.5 LATIN AMERICA
TABLE 254 LATIN AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 255 LATIN AMERICA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 256 LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 257 LATIN AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 258 LATIN AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 259 LATIN AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 260 LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 261 LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 262 LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Gradual increase in pharmaceutical R&D to support market growth
TABLE 263 BRAZIL: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 264 BRAZIL: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 265 BRAZIL: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 266 BRAZIL: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 267 BRAZIL: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 268 BRAZIL: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 269 BRAZIL: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 270 BRAZIL: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.5.2 REST OF LATIN AMERICA
TABLE 271 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 272 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 273 REST OF LATIN AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 274 REST OF LATIN AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 276 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 277 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 278 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.5.3 LATIN AMERICA: RECESSION IMPACT
11.6 MIDDLE EAST
11.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS
TABLE 279 MIDDLE EAST: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 280 MIDDLE EAST: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 281 MIDDLE EAST: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 282 MIDDLE EAST: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 283 MIDDLE EAST: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 284 MIDDLE EAST: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 285 MIDDLE EAST: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 286 MIDDLE EAST: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.6.2 MIDDLE EAST: RECESSION IMPACT
11.7 AFRICA
11.7.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS
TABLE 287 AFRICA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 288 AFRICA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 289 AFRICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 290 AFRICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 291 AFRICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 292 AFRICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 293 AFRICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 294 AFRICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.7.2 AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 KEY PLAYER STRATEGIES
FIGURE 30 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENE THERAPY MARKET
12.2 MARKET SHARE ANALYSIS
FIGURE 31 GENE THERAPY MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
TABLE 295 GENE THERAPY MARKET: DEGREE OF COMPETITION
12.3 REVENUE ANALYSIS
FIGURE 32 REVENUE ANALYSIS FOR KEY COMPANIES (2020–2022)
12.4 COMPANY EVALUATION MATRIX
12.4.1 STARS
12.4.2 EMERGING LEADERS
12.4.3 PERVASIVE PLAYERS
12.4.4 PARTICIPANTS
FIGURE 33 COMPANY EVALUATION MATRIX, 2022
12.4.5 COMPANY FOOTPRINT
12.4.5.1 Company therapeutic area footprint
TABLE 296 THERAPEUTIC AREA FOOTPRINT ANALYSIS OF KEY PLAYERS IN GENE THERAPY MARKET
12.4.5.2 Company regional footprint
TABLE 297 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN GENE THERAPY MARKET
12.5 START-UP/SME EVALUATION MATRIX
12.5.1 PROGRESSIVE COMPANIES
12.5.2 RESPONSIVE COMPANIES
12.5.3 DYNAMIC COMPANIES
12.5.4 STARTING BLOCKS
FIGURE 34 START-UP/SME EVALUATION MATRIX, 2022
12.5.5 COMPETITIVE BENCHMARKING
TABLE 298 GENE THERAPY MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
TABLE 299 GENE THERAPY MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
12.6 COMPETITIVE SCENARIO AND TRENDS
12.6.1 PRODUCT APPROVALS
TABLE 300 GENE THERAPY MARKET: PRODUCT APPROVALS, JANUARY 2020–AUGUST 2023
12.6.2 DEALS
TABLE 301 GENE THERAPY MARKET: DEALS, JANUARY 2020–AUGUST 2023
12.6.3 OTHER DEVELOPMENTS
TABLE 302 GENE THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2020–AUGUST 2023
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 NOVARTIS AG
TABLE 303 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 35 NOVARTIS AG: COMPANY SNAPSHOT (2022)
TABLE 304 NOVARTIS AG: PRODUCT APPROVALS
TABLE 305 NOVARTIS AG: DEALS
TABLE 306 NOVARTIS AG: OTHER DEVELOPMENTS
13.1.2 BIOGEN INC.
TABLE 307 BIOGEN INC.: COMPANY OVERVIEW
FIGURE 36 BIOGEN INC.: COMPANY SNAPSHOT (2022)
TABLE 308 BIOGEN INC.: DEALS
TABLE 309 BIOGEN INC.: OTHER DEVELOPMENTS
13.1.3 GILEAD SCIENCES, INC.
TABLE 310 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
FIGURE 37 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)
TABLE 311 GILEAD SCIENCES, INC.: PRODUCT APPROVALS
TABLE 312 GILEAD SCIENCES, INC.: DEALS
TABLE 313 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS
13.1.4 BRISTOL-MYERS SQUIBB
TABLE 314 BRISTOL-MYERS SQUIBB: COMPANY OVERVIEW
FIGURE 38 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2022)
TABLE 315 BRISTOL-MYERS SQUIBB: PRODUCT APPROVALS
TABLE 316 BRISTOL-MYERS SQUIBB: DEALS
13.1.5 ALNYLAM PHARMACEUTICALS, INC.
TABLE 317 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 39 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
TABLE 318 ALNYLAM PHARMACEUTICALS, INC.: PRODUCT APPROVALS
TABLE 319 ALNYLAM PHARMACEUTICALS, INC.: DEALS
13.1.6 SAREPTA THERAPEUTICS, INC.
TABLE 320 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
FIGURE 40 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)
TABLE 321 SAREPTA THERAPEUTICS, INC.: PRODUCT APPROVALS
TABLE 322 SAREPTA THERAPEUTICS, INC.: DEALS
TABLE 323 SAREPTA THERAPEUTICS, INC.: OTHER DEVELOPMENTS
13.1.7 AMGEN, INC.
TABLE 324 AMGEN, INC.: COMPANY OVERVIEW
FIGURE 41 AMGEN, INC.: COMPANY SNAPSHOT (2022)
TABLE 325 AMGEN, INC.: DEALS
TABLE 326 AMGEN, INC.: OTHER DEVELOPMENTS
13.1.8 ORCHARD THERAPEUTICS PLC
TABLE 327 ORCHARD THERAPEUTICS PLC: COMPANY OVERVIEW
FIGURE 42 ORCHARD THERAPEUTICS PLC: COMPANY SNAPSHOT (2022)
TABLE 328 ORCHARD THERAPEUTICS PLC: PRODUCT APPROVALS
TABLE 329 ORCHARD THERAPEUTICS PLC: DEALS
13.1.9 F. HOFFMANN-LA ROCHE AG
TABLE 330 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
FIGURE 43 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2022)
13.1.10 JAZZ PHARMACEUTICALS PLC
TABLE 331 JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW
FIGURE 44 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2022)
TABLE 332 JAZZ PHARMACEUTICALS PLC: DEALS
13.1.11 UNIQURE N.V.
TABLE 333 UNIQURE N.V.: COMPANY OVERVIEW
FIGURE 45 UNIQURE N.V.: COMPANY SNAPSHOT (2022)
TABLE 334 UNIQURE N.V.: PRODUCT APPROVALS
TABLE 335 UNIQURE N.V.: DEALS
13.1.12 JOHNSON & JOHNSON
TABLE 336 JOHNSON & JOHNSON: COMPANY OVERVIEW
FIGURE 46 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
TABLE 337 JOHNSON & JOHNSON: PRODUCT APPROVALS
TABLE 338 JOHNSON & JOHNSON: DEALS
13.1.13 BLUEBIRD BIO, INC.
TABLE 339 BLUEBIRD BIO, INC.: COMPANY OVERVIEW
FIGURE 47 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT (2022)
TABLE 340 BLUEBIRD BIO, INC.: PRODUCT LAUNCHES & APPROVALS
13.1.14 BIOMARIN PHARMACEUTICAL INC.
TABLE 341 BIOMARIN PHARMACEUTICAL INC.: COMPANY OVERVIEW
FIGURE 48 BIOMARIN PHARMACEUTICAL INC.: COMPANY SNAPSHOT (2022)
TABLE 342 BIOMARIN PHARMACEUTICAL INC.: DEALS
TABLE 343 BIOMARIN PHARMACEUTICAL INC.: PRODUCT APPROVALS
13.1.15 KRYSTAL BIOTECH, INC.
TABLE 344 KRYSTAL BIOTECH, INC.: COMPANY OVERVIEW
TABLE 345 KRYSTAL BIOTECH, INC.: PRODUCT APPROVALS
TABLE 346 KRYSTAL BIOTECH, INC.: DEALS
TABLE 347 KRYSTAL BIOTECH, INC.: OTHER DEVELOPMENTS
13.1.16 SHANGHAI SUNWAY BIOTECH CO. LTD.
TABLE 348 SHANGHAI SUNWAY BIOTECH CO. LTD.: COMPANY OVERVIEW
13.1.17 SIBIONO GENETECH CO. LTD.
TABLE 349 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW
13.2 OTHER PLAYERS
13.2.1 FERRING B.V.
13.2.2 VERTEX PHARMACEUTICALS INCORPORATED
13.2.3 PFIZER, INC.
13.2.4 SANGAMO THERAPEUTICS, INC.
13.2.5 REGENXBIO
13.2.6 ULTRAGENYX PHARMACEUTICAL INC.
13.2.7 MEIRAGTX HOLDINGS PLC
13.2.8 ANGES, INC.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 GENE THERAPY MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 GENE THERAPY MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION OF GENE THERAPY MARKET
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
FIGURE 5 MARKET SIZE ESTIMATION FOR GENE THERAPY MARKET: REVENUE SHARE ANALYSIS
2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH FORECAST
FIGURE 8 GENE THERAPY MARKET: CAGR PROJECTIONS
FIGURE 9 GENE THERAPY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
3 EXECUTIVE SUMMARY
FIGURE 11 GENE THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 12 GENE THERAPY MARKET, BY VECTOR, 2023 VS. 2028 (USD MILLION)
FIGURE 13 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
FIGURE 14 GENE THERAPY MARKET, BY DELIVERY METHOD, 2023 VS. 2028 (USD MILLION)
FIGURE 15 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF GENE THERAPY MARKET
4 PREMIUM INSIGHTS
4.1 GENE THERAPY MARKET OVERVIEW
FIGURE 17 INCREASING INVESTMENTS IN GENE THERAPY RESEARCH TO DRIVE GROWTH IN GENE THERAPY MARKET
4.2 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA & COUNTRY (2022)
FIGURE 18 NEUROLOGY ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
4.3 GENE THERAPY MARKET, BY VECTOR, 2022
FIGURE 19 VIRAL VECTORS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 GENE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 GENE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing regulatory approvals for gene therapy products
TABLE 2 LIST OF KEY PRODUCT APPROVALS IN GENE THERAPY MARKET, 2021–2023
5.2.1.2 Increasing investments in gene therapy research
5.2.1.3 Growing technological advancements
TABLE 3 LIST OF ADVANCED PLATFORMS LAUNCHED IN GENE THERAPY MARKET, 2022–2023
5.2.1.4 Rising prevalence of genetic disorders and cancer
5.2.2 RESTRAINTS
5.2.2.1 High cost of gene therapy products
TABLE 4 COST OF GENE THERAPY PRODUCTS
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for cell & gene therapies
5.2.3.2 Increasing focus on precision medicine
5.2.4 CHALLENGES
5.2.4.1 Complex manufacturing process
5.2.4.2 Short shelf life and supply chain challenges
5.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 GENE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 TECHNOLOGY ANALYSIS
5.5 VALUE CHAIN ANALYSIS
FIGURE 22 GENE THERAPY MARKET: VALUE CHAIN
5.6 ECOSYSTEM ANALYSIS
FIGURE 23 GENE THERAPY MARKET: ECOSYSTEM MAP
5.7 PATENT ANALYSIS
FIGURE 24 PATENT APPLICATIONS FOR GENE THERAPY PRODUCTS, JANUARY 2012–SEPTEMBER 2023
TABLE 6 GENE THERAPY MARKET: INDICATIVE LIST OF PATENTS
5.8 PIPELINE ANALYSIS
TABLE 7 GENE THERAPY PRODUCTS IN CLINICAL PIPELINE
5.9 SUPPLY CHAIN ANALYSIS
FIGURE 25 GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS
TABLE 8 SUPPLY CHAIN ECOSYSTEM
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY ANALYSIS
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS
TABLE 13 AVERAGE SELLING PRICE OF GENE THERAPY PRODUCTS
TABLE 14 AVERAGE SELLING PRICE OF GENE THERAPY PRODUCTS, BY DELIVERY METHOD
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13 KEY CONFERENCES & EVENTS
TABLE 15 GENE THERAPY MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023–2024)
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS ON BUYING PROCESS
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR GENE THERAPY PRODUCTS IN HOSPITALS AND CLINICS
5.14.2 BUYING CRITERIA FOR GENE THERAPY MARKET
FIGURE 27 KEY BUYING CRITERIA FOR HOSPITALS AND CLINICS
6 GENE THERAPY MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 16 GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
6.2 GENE SILENCING
6.2.1 HIGH FLEXIBILITY AND PRECISION OFFERED BY GENE SILENCING THERAPIES TO SUPPORT GROWTH
TABLE 17 GENE SILENCING THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 18 NORTH AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 19 EUROPE: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 20 ASIA PACIFIC: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 21 LATIN AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 CELL REPLACEMENT
6.3.1 LONG-TERM EFFECTS OF CELL REPLACEMENT THERAPY TO BOOST ADOPTION
TABLE 22 CELL REPLACEMENT THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 23 NORTH AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 EUROPE: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 ASIA PACIFIC: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 LATIN AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 GENE AUGMENTATION
6.4.1 GROWING USE OF GENE AUGMENTATION THERAPY AGAINST MONOGENIC DISORDERS TO FAVOR MARKET GROWTH
TABLE 27 GENE AUGMENTATION THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 28 NORTH AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 EUROPE: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 ASIA PACIFIC: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 LATIN AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.5 OTHER THERAPIES
7 GENE THERAPY MARKET, BY VECTOR
7.1 INTRODUCTION
TABLE 32 GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
7.2 VIRAL VECTORS
TABLE 33 GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 34 GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 35 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 LATIN AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.1 RETROVIRAL VECTORS
TABLE 39 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 40 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 41 NORTH AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 LATIN AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.1.1 Gamma retroviral vectors
7.2.1.1.1 Availability of wide range of gamma-retroviral vectors to support market growth
TABLE 45 GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 46 NORTH AMERICA: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 EUROPE: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 ASIA PACIFIC: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 49 LATIN AMERICA: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.1.2 Lentiviral vectors
7.2.1.2.1 North America to dominate lentiviral vectors market
TABLE 50 GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 51 NORTH AMERICA: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 LATIN AMERICA: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.2 ADENO-ASSOCIATED VIRAL VECTORS
7.2.2.1 Growing clinical pipeline of adeno-associated viral vectors to drive growth
TABLE 55 GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 56 NORTH AMERICA: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 57 EUROPE: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 ASIA PACIFIC: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 LATIN AMERICA: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.3 OTHER VIRAL VECTORS
TABLE 60 GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 61 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 EUROPE: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 NON-VIRAL VECTORS
TABLE 65 GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 66 GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 67 NORTH AMERICA: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 68 EUROPE: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 69 ASIA PACIFIC: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 LATIN AMERICA: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
7.3.1 OLIGONUCLEOTIDES
7.3.1.1 Oligonucleotides to account for largest share of non-viral vectors market
TABLE 71 GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY REGION, 2021–2028 (USD MILLION)
TABLE 72 NORTH AMERICA: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 73 EUROPE: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 74 ASIA PACIFIC: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 75 LATIN AMERICA: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021–2028 (USD MILLION)
7.3.2 OTHER NON-VIRAL VECTORS
TABLE 76 GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 77 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 EUROPE: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021–2028 (USD MILLION)
8 GENE THERAPY MARKET, BY THERAPEUTIC AREA
8.1 INTRODUCTION
TABLE 81 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
8.2 NEUROLOGY
8.2.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH
TABLE 82 GENE THERAPY MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 83 NORTH AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 EUROPE: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 86 LATIN AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 ONCOLOGY
8.3.1 GROWING DEMAND FOR TARGETED THERAPIES AGAINST CANCERS TO DRIVE MARKET GROWTH
TABLE 87 PIPELINE PRODUCTS FOR ONCOLOGY APPLICATIONS
TABLE 88 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040
TABLE 89 GENE THERAPY MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 90 NORTH AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 91 EUROPE: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 92 ASIA PACIFIC: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 93 LATIN AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 HEPATOLOGY
8.4.1 GROWING R&D ACTIVITIES FOR LIVER CONDITIONS TO SUPPORT GROWTH
TABLE 94 GENE THERAPY MARKET FOR HEPATOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 95 NORTH AMERICA: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 EUROPE: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 ASIA PACIFIC: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 98 LATIN AMERICA: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
8.5 OTHER THERAPEUTIC AREAS
TABLE 99 GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)
TABLE 100 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 EUROPE: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 102 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
9 GENE THERAPY MARKET, BY DELIVERY METHOD
9.1 INTRODUCTION
TABLE 104 GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
9.2 IN VIVO
9.2.1 IN VIVO DELIVERY METHOD TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
TABLE 105 COMMERCIALIZED AND PIPELINE IN VIVO-BASED GENE THERAPY PRODUCTS
TABLE 106 IN VIVO GENE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 107 NORTH AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 108 EUROPE: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 109 ASIA PACIFIC: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 110 LATIN AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 EX VIVO
9.3.1 GROWING FOCUS ON ONCOLOGY BY MARKET PLAYERS TO SUPPORT MARKET GROWTH
TABLE 111 COMMERCIALIZED AND PIPELINE EX VIVO-BASED GENE THERAPY PRODUCTS
TABLE 112 EX VIVO GENE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 113 NORTH AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 114 EUROPE: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 115 ASIA PACIFIC: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 116 LATIN AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION
10.1 INTRODUCTION
TABLE 117 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
10.2 INTRAVENOUS
10.2.1 EFFECTIVENESS OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH
TABLE 118 GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 119 NORTH AMERICA: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 120 EUROPE: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 121 ASIA PACIFIC: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 122 LATIN AMERICA: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
10.3 OTHER ROUTES OF ADMINISTRATION
TABLE 123 GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 124 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 125 EUROPE: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 126 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 127 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
11 GENE THERAPY MARKET, BY REGION
11.1 INTRODUCTION
TABLE 128 GENE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT
TABLE 129 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 130 NORTH AMERICA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 131 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 132 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 133 NORTH AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 134 NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 135 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 136 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 137 NORTH AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.2.1 US
11.2.1.1 Growing regulatory approvals and availability of advanced treatments to drive market growth
TABLE 138 US FDA APPROVALS FOR GENE THERAPY PRODUCTS
TABLE 139 US: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 140 US: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 141 US: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 142 US: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 143 US: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 144 US: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 145 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 146 US: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Growing gene therapy research initiatives to support growth
TABLE 147 CANADA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 148 CANADA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 149 CANADA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 150 CANADA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 151 CANADA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 152 CANADA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 153 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 154 CANADA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.2.3 NORTH AMERICA: RECESSION IMPACT
11.3 EUROPE
FIGURE 29 EUROPE: GENE THERAPY MARKET SNAPSHOT
TABLE 155 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 156 EUROPE: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 157 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 158 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 159 EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 160 EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 161 EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 162 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 163 EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Growing collaborations in market to boost growth
TABLE 164 GERMANY: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 165 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 166 GERMANY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 167 GERMANY: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 168 GERMANY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 169 GERMANY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 170 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 171 GERMANY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.2 UK
11.3.2.1 Strong government support to drive market growth
TABLE 172 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 173 UK: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 174 UK: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 175 UK: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 176 UK: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 177 UK: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 178 UK: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 179 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 180 UK: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Increasing initiatives in genomic research to drive market
TABLE 181 FRANCE: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 182 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 183 FRANCE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 184 FRANCE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 185 FRANCE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 186 FRANCE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 187 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 188 FRANCE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Initiatives for gene therapy development to drive growth
TABLE 189 ITALY: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 190 ITALY: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 191 ITALY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 192 ITALY: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 193 ITALY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 194 ITALY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 195 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 196 ITALY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Genomics initiatives and funding to support market growth
TABLE 197 SPAIN: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 198 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 199 SPAIN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 200 SPAIN: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 201 SPAIN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 202 SPAIN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 203 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 204 SPAIN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 205 REST OF EUROPE: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 206 REST OF EUROPE: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 207 REST OF EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 208 REST OF EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 209 REST OF EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 210 REST OF EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 211 REST OF EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 212 REST OF EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.3.7 EUROPE: RECESSION IMPACT
11.4 ASIA PACIFIC
TABLE 213 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 214 ASIA PACIFIC: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 215 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 216 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 217 ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 218 ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 219 ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 220 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 221 ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.4.1 CHINA
11.4.1.1 China to dominate gene therapy market in APAC during forecast period
TABLE 222 CHINA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 223 CHINA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 224 CHINA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 225 CHINA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 226 CHINA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 227 CHINA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 228 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 229 CHINA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Increasing initiatives supporting gene therapy adoption to propel market growth
TABLE 230 JAPAN: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 231 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 232 JAPAN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 233 JAPAN: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 234 JAPAN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 235 JAPAN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 236 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 237 JAPAN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Increasing burden of chronic diseases to drive market growth
TABLE 238 INDIA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 239 INDIA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 240 INDIA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 241 INDIA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 242 INDIA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 243 INDIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 244 INDIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 245 INDIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 246 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 247 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 248 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 249 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 250 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 251 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 252 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 253 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.4.5 ASIA PACIFIC: RECESSION IMPACT
11.5 LATIN AMERICA
TABLE 254 LATIN AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 255 LATIN AMERICA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 256 LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 257 LATIN AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 258 LATIN AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 259 LATIN AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 260 LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 261 LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 262 LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Gradual increase in pharmaceutical R&D to support market growth
TABLE 263 BRAZIL: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 264 BRAZIL: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 265 BRAZIL: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 266 BRAZIL: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 267 BRAZIL: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 268 BRAZIL: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 269 BRAZIL: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 270 BRAZIL: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.5.2 REST OF LATIN AMERICA
TABLE 271 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 272 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 273 REST OF LATIN AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 274 REST OF LATIN AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 276 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 277 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 278 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.5.3 LATIN AMERICA: RECESSION IMPACT
11.6 MIDDLE EAST
11.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS
TABLE 279 MIDDLE EAST: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 280 MIDDLE EAST: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 281 MIDDLE EAST: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 282 MIDDLE EAST: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 283 MIDDLE EAST: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 284 MIDDLE EAST: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 285 MIDDLE EAST: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 286 MIDDLE EAST: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.6.2 MIDDLE EAST: RECESSION IMPACT
11.7 AFRICA
11.7.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS
TABLE 287 AFRICA: GENE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 288 AFRICA: GENE THERAPY MARKET, BY VECTOR, 2021–2028 (USD MILLION)
TABLE 289 AFRICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 290 AFRICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 291 AFRICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 292 AFRICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
TABLE 293 AFRICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021–2028 (USD MILLION)
TABLE 294 AFRICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
11.7.2 AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 KEY PLAYER STRATEGIES
FIGURE 30 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENE THERAPY MARKET
12.2 MARKET SHARE ANALYSIS
FIGURE 31 GENE THERAPY MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
TABLE 295 GENE THERAPY MARKET: DEGREE OF COMPETITION
12.3 REVENUE ANALYSIS
FIGURE 32 REVENUE ANALYSIS FOR KEY COMPANIES (2020–2022)
12.4 COMPANY EVALUATION MATRIX
12.4.1 STARS
12.4.2 EMERGING LEADERS
12.4.3 PERVASIVE PLAYERS
12.4.4 PARTICIPANTS
FIGURE 33 COMPANY EVALUATION MATRIX, 2022
12.4.5 COMPANY FOOTPRINT
12.4.5.1 Company therapeutic area footprint
TABLE 296 THERAPEUTIC AREA FOOTPRINT ANALYSIS OF KEY PLAYERS IN GENE THERAPY MARKET
12.4.5.2 Company regional footprint
TABLE 297 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN GENE THERAPY MARKET
12.5 START-UP/SME EVALUATION MATRIX
12.5.1 PROGRESSIVE COMPANIES
12.5.2 RESPONSIVE COMPANIES
12.5.3 DYNAMIC COMPANIES
12.5.4 STARTING BLOCKS
FIGURE 34 START-UP/SME EVALUATION MATRIX, 2022
12.5.5 COMPETITIVE BENCHMARKING
TABLE 298 GENE THERAPY MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
TABLE 299 GENE THERAPY MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
12.6 COMPETITIVE SCENARIO AND TRENDS
12.6.1 PRODUCT APPROVALS
TABLE 300 GENE THERAPY MARKET: PRODUCT APPROVALS, JANUARY 2020–AUGUST 2023
12.6.2 DEALS
TABLE 301 GENE THERAPY MARKET: DEALS, JANUARY 2020–AUGUST 2023
12.6.3 OTHER DEVELOPMENTS
TABLE 302 GENE THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2020–AUGUST 2023
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 NOVARTIS AG
TABLE 303 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 35 NOVARTIS AG: COMPANY SNAPSHOT (2022)
TABLE 304 NOVARTIS AG: PRODUCT APPROVALS
TABLE 305 NOVARTIS AG: DEALS
TABLE 306 NOVARTIS AG: OTHER DEVELOPMENTS
13.1.2 BIOGEN INC.
TABLE 307 BIOGEN INC.: COMPANY OVERVIEW
FIGURE 36 BIOGEN INC.: COMPANY SNAPSHOT (2022)
TABLE 308 BIOGEN INC.: DEALS
TABLE 309 BIOGEN INC.: OTHER DEVELOPMENTS
13.1.3 GILEAD SCIENCES, INC.
TABLE 310 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
FIGURE 37 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)
TABLE 311 GILEAD SCIENCES, INC.: PRODUCT APPROVALS
TABLE 312 GILEAD SCIENCES, INC.: DEALS
TABLE 313 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS
13.1.4 BRISTOL-MYERS SQUIBB
TABLE 314 BRISTOL-MYERS SQUIBB: COMPANY OVERVIEW
FIGURE 38 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2022)
TABLE 315 BRISTOL-MYERS SQUIBB: PRODUCT APPROVALS
TABLE 316 BRISTOL-MYERS SQUIBB: DEALS
13.1.5 ALNYLAM PHARMACEUTICALS, INC.
TABLE 317 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 39 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
TABLE 318 ALNYLAM PHARMACEUTICALS, INC.: PRODUCT APPROVALS
TABLE 319 ALNYLAM PHARMACEUTICALS, INC.: DEALS
13.1.6 SAREPTA THERAPEUTICS, INC.
TABLE 320 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
FIGURE 40 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)
TABLE 321 SAREPTA THERAPEUTICS, INC.: PRODUCT APPROVALS
TABLE 322 SAREPTA THERAPEUTICS, INC.: DEALS
TABLE 323 SAREPTA THERAPEUTICS, INC.: OTHER DEVELOPMENTS
13.1.7 AMGEN, INC.
TABLE 324 AMGEN, INC.: COMPANY OVERVIEW
FIGURE 41 AMGEN, INC.: COMPANY SNAPSHOT (2022)
TABLE 325 AMGEN, INC.: DEALS
TABLE 326 AMGEN, INC.: OTHER DEVELOPMENTS
13.1.8 ORCHARD THERAPEUTICS PLC
TABLE 327 ORCHARD THERAPEUTICS PLC: COMPANY OVERVIEW
FIGURE 42 ORCHARD THERAPEUTICS PLC: COMPANY SNAPSHOT (2022)
TABLE 328 ORCHARD THERAPEUTICS PLC: PRODUCT APPROVALS
TABLE 329 ORCHARD THERAPEUTICS PLC: DEALS
13.1.9 F. HOFFMANN-LA ROCHE AG
TABLE 330 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
FIGURE 43 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2022)
13.1.10 JAZZ PHARMACEUTICALS PLC
TABLE 331 JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW
FIGURE 44 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2022)
TABLE 332 JAZZ PHARMACEUTICALS PLC: DEALS
13.1.11 UNIQURE N.V.
TABLE 333 UNIQURE N.V.: COMPANY OVERVIEW
FIGURE 45 UNIQURE N.V.: COMPANY SNAPSHOT (2022)
TABLE 334 UNIQURE N.V.: PRODUCT APPROVALS
TABLE 335 UNIQURE N.V.: DEALS
13.1.12 JOHNSON & JOHNSON
TABLE 336 JOHNSON & JOHNSON: COMPANY OVERVIEW
FIGURE 46 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
TABLE 337 JOHNSON & JOHNSON: PRODUCT APPROVALS
TABLE 338 JOHNSON & JOHNSON: DEALS
13.1.13 BLUEBIRD BIO, INC.
TABLE 339 BLUEBIRD BIO, INC.: COMPANY OVERVIEW
FIGURE 47 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT (2022)
TABLE 340 BLUEBIRD BIO, INC.: PRODUCT LAUNCHES & APPROVALS
13.1.14 BIOMARIN PHARMACEUTICAL INC.
TABLE 341 BIOMARIN PHARMACEUTICAL INC.: COMPANY OVERVIEW
FIGURE 48 BIOMARIN PHARMACEUTICAL INC.: COMPANY SNAPSHOT (2022)
TABLE 342 BIOMARIN PHARMACEUTICAL INC.: DEALS
TABLE 343 BIOMARIN PHARMACEUTICAL INC.: PRODUCT APPROVALS
13.1.15 KRYSTAL BIOTECH, INC.
TABLE 344 KRYSTAL BIOTECH, INC.: COMPANY OVERVIEW
TABLE 345 KRYSTAL BIOTECH, INC.: PRODUCT APPROVALS
TABLE 346 KRYSTAL BIOTECH, INC.: DEALS
TABLE 347 KRYSTAL BIOTECH, INC.: OTHER DEVELOPMENTS
13.1.16 SHANGHAI SUNWAY BIOTECH CO. LTD.
TABLE 348 SHANGHAI SUNWAY BIOTECH CO. LTD.: COMPANY OVERVIEW
13.1.17 SIBIONO GENETECH CO. LTD.
TABLE 349 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW
13.2 OTHER PLAYERS
13.2.1 FERRING B.V.
13.2.2 VERTEX PHARMACEUTICALS INCORPORATED
13.2.3 PFIZER, INC.
13.2.4 SANGAMO THERAPEUTICS, INC.
13.2.5 REGENXBIO
13.2.6 ULTRAGENYX PHARMACEUTICAL INC.
13.2.7 MEIRAGTX HOLDINGS PLC
13.2.8 ANGES, INC.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
